We are live on
!
Find out more
EUCRU
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU
Delisted
EUCRU was delisted on the 26th of April, 2023.
19 hedge funds and large institutions have $18.4M invested in Eucrates Biomedical Acquisition Corp. Unit in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
36% more funds holding
Funds holding: 14 → 19 (+5)
32% less capital invested
Capital invested by funds: $27.1M → $18.4M (-$8.7M)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Holders
19
Holders Change
+5
Holders Change %
+35.71%
% of All Funds
0.3%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
Top Sellers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.29M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.99M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$436K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$100K |
| 5 |
CS
Clear Street
New York
|
-$90K |